WO1992015284A1 - Gas and oxygen carrying lipid vesicles - Google Patents

Gas and oxygen carrying lipid vesicles Download PDF

Info

Publication number
WO1992015284A1
WO1992015284A1 PCT/US1992/001584 US9201584W WO9215284A1 WO 1992015284 A1 WO1992015284 A1 WO 1992015284A1 US 9201584 W US9201584 W US 9201584W WO 9215284 A1 WO9215284 A1 WO 9215284A1
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
paucilamellar
vesicles
vesicle
filled
Prior art date
Application number
PCT/US1992/001584
Other languages
French (fr)
Inventor
Sheryl Lynn Henderson
Donald F. H. Wallach
Rajiv Mathur
Original Assignee
Micro Vesicular Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micro Vesicular Systems, Inc. filed Critical Micro Vesicular Systems, Inc.
Priority to JP4507835A priority Critical patent/JPH06507830A/en
Priority to AU15388/92A priority patent/AU660970B2/en
Publication of WO1992015284A1 publication Critical patent/WO1992015284A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026Blood substitute; Oxygen transporting formulations; Plasma extender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/22Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22Peroxides; Oxygen; Ozone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A61K8/70Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • A61K9/1278Post-loading, e.g. by ion or pH gradient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02Making microcapsules or microballoons
    • B01J13/20After-treatment of capsule walls, e.g. hardening
    • B01J13/203Exchange of core-forming material by diffusion through the capsule wall
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0008Detergent materials or soaps characterised by their shape or physical properties aqueous liquid non soap compositions
    • C11D17/0017Multi-phase liquid compositions
    • C11D17/0021Aqueous microemulsions
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0008Detergent materials or soaps characterised by their shape or physical properties aqueous liquid non soap compositions
    • C11D17/0026Structured liquid compositions, e.g. liquid crystalline phases or network containing non-Newtonian phase
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/829Liposomes, e.g. encapsulation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]

Definitions

  • a nonvolatile hydrophobic material such as a paraffin wax
  • a nonvolatile hydrophobic material such as a paraffin wax
  • vesicles have a monolayer of a surfactant surrounding the hydrophobic core, either from cannibalizing the wall material or by adding a separate, indifferent (or nonvesicle forming surfactant) in the manufacture of the vesicle.
  • the surfactant stabilized wax droplets limit the collapse of this central core, forming tiny, solid particles and leading to relatively easy rehydration.
  • the present invention relates to the use of moderately volatile liquids as an attempt to solve the problem.
  • moderately volatile liquid means and implies a liquid that is less volatile than water but more volatile than the lipids which form the bilayer structure of the vesicles.
  • These moderately volatile liquids have a vapor pressure such that they are able to leach out of the lipid vesicles when air dried, dried under a vacuum, or lyophilized, but they do so at a slower rate than the encapsulated aqueous solution. Accordingly, substantially all of the aqueous solution encapsulated in the vesicle, as well as the aqueous solution surrounding the vesicle, evaporates before the moderately volatile liquid and the moderately volatile liquid provides structure to the vesicle as the water is removed.
  • perfluorocarbons are, primarily, alkanes or cycloalkanes having all of the hydrogens replaced with fluorines. Certain of these perfluorocarbons, primarily, perfluorodecalin and perfluorotripropylamine, have an additional advantage; they can function as oxygen carriers. Most perfluorocarbons have a density of about two, have a high air-and oxygen-carrying capacity, and are substantially unreactive with most materials.
  • Encapsulation of oxygen-rich perfluorocarbons could have substantial value for use in cosmetics or in fermentation because of their high in vitro oxygenation capacity.
  • these materials have promise for a substantial number of medical uses. For example, for these materials would be advantageous if used as an infusion after trauma, for infusion for radiotherapy, for wound perfusion, in angioplasty, or in radioimaging.
  • an object of the invention is to provide a method of encapsulating perfluorocarbons and other moderately volatile liquids.
  • Another object of the invention is to provide a method of forming gas-filled lipid vesicles.
  • a further object of the invention is to provide a whitener which could be used in a variety of industrial applications.
  • Paucilamellar lipid vesicles having a moderately volatile liquid encapsulated therein have 2-10 lipid bilayers surrounding the large, amorphous central cavity.
  • the first step in manufacturing these vesicles is forming a lipid phase by blending the wall-forming lipid (which provides the structure to the vesicles) and any other lipid soluble materials which are to be incorporated into the walls.
  • One lipid soluble material which is often used is a sterol such as cholesterol which assists in the thermotropic phase transition. If any oil distinct from the moderately volatile liquid is to be encapsulated into the central cavity, it can be added at this stage or "cold loaded" later.
  • the vessels can then be "cold loaded” with a moderately volatile liquid using the techniques described in United States Patent Application Serial No. 598,120.
  • any oil to be carried by the vesicles is loaded at this stage using the same procedure.
  • the formed vesicles are mixed with the moderately volatile liquid under gentle to moderate shear conditions, thereby encapsulating the moderately volatile liquid in the central cavity and driving off some (or all) of the water from the core.
  • “hot loading” of the vesicles with the moderately volatile liquid is preferred. This is accomplished by dispersing or premixing the moderately volatile liquid in the lipid phase before hydration. This allows the hydration and mixing steps to be carried out simultaneously. However, using the "hot loading” technique, special care must be taken to keep the lipid phase homogeneous during hydration.
  • the paucilamellar lipid vesicles having the moderately volatile liquid encapsulated therein are to be used as is, they are merely separated from the reactants. However, if gas-filled, e.g., air-filled, paucilamellar lipid vesicles are being formed, the aqueous solution and the moderately volatile liquid must be removed. This is accomplished by evaporating both liquids, e.g., by air drying, vacuum drying, or lyophilization of the vesicles. Vacuum drying is preferred.
  • the gas-filled paucilamellar lipid vesicles may be used as a whitener because of their refractive properties.
  • Nonionic lipids e.g., nonionic surfactants
  • these nonionic lipids are preferably polyethylene fatty acid esters, polyethylene fatty acid ethers, diethanola ides, long chain acyl hexosa ides, long chain acyl amino acid amides, long chain amino acid amines, polyoxyethylene sorbitan esters, polyoxy glycerol mono-and diesters, glycerol mono-and distearate, glycerol mono-and dioleate, glycerol mono-and dipalmitate, and mixtures thereof.
  • the most preferred lipids have a melting temperature of about 40°C.
  • nonionic lipids certain charged lipids such as sarcosinates (sarcosinamides), betaines, and monomeric and dimeric alkyds have been found to be useful.
  • phospholipids such as phosphatidylcholine can be used.
  • An additional structural support material may be added to further stabilize the vesicles.
  • This additional material is preferably a water soluble polymerizable material that provides additional structural support to the vesicles upon polymerization.
  • Preferred water soluble polymerizable materials are gelatins, acrylates, acrylamides, alginates, carboxymethylcellulose, and similar polymers.
  • Paucilamellar lipid vesicles having aqueous or oil-filled central cavities can be manufactured using standard techniques such as those disclosed in United States Patent No. 4,911,928 or United States Patent No. 4,855,090, the disclosure of which is also incorporated herein by reference. These vesicles are then "cold loaded" with the moderately volatile liquid by mixing the preformed vesicles with the moderately volatile liquid, preferably under gentle to moderate shear conditions. A syringe technique such as is described in United States Patent Application Serial No. 598,120 is preferred. This technique provides a liquid shear which is approximately equal to a relative flow rate of about 5-50 m/s though a 1 mm radius orifice.
  • the perfluorocarbons are the preferred moderately volatile liquids but other materials such as certain silicone oils or volatile mineral spirits can also be used.
  • the primary requirements are unreactivity with the lipid wall structure, immiscibility between the moderately volatile liquid and the lipid and aqueous solutions (as well as any oil to be encapsulated) and the ability to be evaporated from the vesicle without damaging the vesicle at a rate slower than the water is evaporated.
  • Evaporation of the aqueous solutions and moderately volatile liquid can be carried out by a variety of methods. However, high heat evaporation should not be used as the lipid structure itself will be melted if too much heat is applied, thereby degrading the vesicles and defeating the purpose of the procedure. Similarly, too high a vacuum cannot be used. While lyophilization is an effective method of removing the liquids, it may be unnecessarily expensive except for large bulk production.
  • test solution was water (designated "O"), perfluorooctane (a perfluorocarbon) or cyclomethicone (a silicone oil).
  • O water
  • perfluorooctane a perfluorocarbon
  • cyclomethicone a silicone oil
  • This Example indicates that there clearly is a void formed in the moderately volatile liquid vesicles after drying. Further, it indicates that a material like a perfluorocarbon is preferred to a cyclomethicone because of the greater white (or refractile) intensity.
  • Example 2 a similar test to that described in Example 1 was carried out except the lipid used to form the vesicle was polyoxyethylene-4 stearyl alcohol in lieu of the polyoxyethylene-9 glyceryl monostearate.
  • the vesicles were prepared using 4 ml of the heated lipid solution and 16 ml of an aqueous solution, either with or without gelatin in the aqueous phase. Again, the lipid phase was heated to approximately 70°C, the aqueous phase was heated to approximately 65°C, and the phases were blended using the syringe method described in Example 1.
  • the first three samples (A-C) act as controls for the other samples.
  • the solution was merely hazy if no moderately volatile liquid was used.
  • heterogenous large vesicles had been apparent. These materials did not rehydrate into vesicles.
  • Sample D also looked hazy under the oil but was somewhat more opaque than the control samples. Upon rehydration, vesicles reformed, showing that the bilayer structure still existed. Similar results were expected from samples F and H but no observation was made upon hydration.
  • Sample E containing encapsulated perfluorooctane, showed results similar to those described in Example 1.
  • This sample when viewed under oil, was white and opaque, showing a network of vesicles. Upon rehydrating, detached vesicles were abundant. Similarly, sample G was also opaque but the vesicles seemed slightly distorted. Upon rehydration, the vesicles were more tightly held than those of sample E, e.g., they did not flow as much. The rehydrated vesicles for sample G appeared to be in the form of sheets of defined vesicles. Sample I gave similar results to sample G.
  • This Example establishes that the described procedure for vesicle manufacture having a moderately volatile liquid will form vesicles with a central void upon dehydration and that vesicles can be formed upon rehydration.
  • the vesicles were made by blending 4 ml of polyoxyethylene-9 glyceryl monostearate with 16 ml of deionized water using the syringe technique of Example 1. After separation of the vesicles, and cooling to room temperature, 10 ml of the formed vesicles were blended with 2 ml of a mixture of 0.1% oil red 0 in mineral oil (Drakeol 19). The dye-containing oil and vesicles were syringed by the procedure of Example 1 for approximately two minutes, providing encapsulation of the oil. About 12 ml of the oil-filled vesicles were then blended with 2 ml of perfluorodecalin using the syringe technique of Example 1. The sample was observed under a light microscope before and after the addition of the perfluorodecalin. After observation, the vesicles were centrifuged for fifteen minutes at 3500 rpm. No separation of dye or perfluorodecalin was observed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

The present invention relates to the production of lipid vesicles having a moderately volatile material such as a perfluorocarbon or a silicone oil encapsulated therein. In another aspect, lipid vesicles having a gas-filled center or core are made. The lipid vesicles having gas-filled central core are made by dehydrating vesicles having the moderately volatile liquid encapsulated in the central core. This drives off the water first, allowing the moderately volatile liquid to stabilize the vesicle structure as it dries, finally forming a central void which can refract light. The preferred vesicles of the invention are paucilamellar vesicles.

Description

GAS AND OXYGEN CARRYING LIPID VESICLES
Reference to Related Applications
This application is a continuation-in-part of United States Patent Application Serial No. 598,120, filed October 16, 1990, entitled "Method of Making Oil Filled Paucilamellar Lipid Vesicles," which is a continuation-in-part of United States Patent Application Serial No. 410,650, filed September 2, 1989, entitled "Liposomal Cleaner," which is a continuation-in-part of United States Patent No. 4,911,928, issued March 27, 1990, entitled "Paucilamellar Lipid Vesicles." United States Patent Application Serial No. 598,120 is also a continuation-in-part of United States Patent Application Serial No. 443,516, filed November 29, 1989, entitled "Paucilamellar Lipid Vesicles," which is a continuation of the aforementioned United States Patent No. 4,911,928. The disclosures of all the above applications and patents are incorporated herein by reference.
Background of the Invention
The present invention concerns certain special purpose lipid vesicles, specifically lipid vesicles with voids and oxygen carrying capacity. These special lipid vesicles have significant uses industrially. The vesicles with voids can be used as whiteners for the paint industry, while oxygen carrying vesicles are particularly useful in the biological sciences, e.g., as artificial oxygen suppliers. While the different aspects of the invention may appear somewhat diverse, the broad applicability of the methods described herein to both aspects of the invention shall be readily apparent from the following description.
Paucilamellar lipid vesicles, e.g., those described in United States Patent No. 4,911,928, the disclosure of which is incorporated herein by reference, have 2-10 substantially spherical lipid bilayers surrounding a large, amorphous cavity or core. The lipid bilayers are hydrated, having bound water entrapped between the bilayers. The central cavity may encapsulate an aqueous solution, or a water immiscible oil or wax can fill part or all of the core.
There have been numerous attempts at drying aqueous filled lipid vesicles, primarily using a variety of lyophilization methods. In most instances, a cryoprotectant such as high molecular weight dextran or other carbohydrate has been used to preserve the lipid wall structure as the aqueous solution is removed. Without this cryoprotectant, the dehydrated bilayers collapse, forming a solid bilamellar array which is often distinguishable microscopically by visible optical bifringence. These lyophilization methods have been moderately successful, allowing rehydration (and, accordingly, reconstitution) of the lipid vesicles. The cryoprotectants are deposited around the bilayers, allowing reformation of the vesicles from the lamellar skeleton-, upon rehydration. However, unless rehydration is by using a vapor rather than liquid phase, there normally is some loss of encapsulated water soluble material into the external aqueous phase. The use of cryoprotectants provides a measure of stability to the spherical bilayer shells by preventing the aggregation of vesicles during dehydration. This does not prevent collapse of the vesicle core for paucilamellar lipid vesicles.
The situation is somewhat different if a nonvolatile hydrophobic material such as a paraffin wax is encapsulated in the amorphous central cavity of a paucilamellar vesicle. These vesicles have a monolayer of a surfactant surrounding the hydrophobic core, either from cannibalizing the wall material or by adding a separate, indifferent (or nonvesicle forming surfactant) in the manufacture of the vesicle. As the water is removed, the surfactant stabilized wax droplets limit the collapse of this central core, forming tiny, solid particles and leading to relatively easy rehydration.
While it is possible to make vesicles with a hydrophobic core encapsulating a liquid which is more volatile than the aqueous solution bound in the bilayers, this procedure does not lead to dry vesicles with a void in the center. These volatile materials, e.g., organic solvents, volatilize before the water as the vesicles are dried. As the drying continues, the core which had been filled by the volatile material leaches water from the bilayers into the central cavity. The vesicles shrink, forming small aqueous filled paucilamellar lipid vesicles that give up their water as if there had never been any volatile liquid in the core.
None of the described methods have provided means for forming stable, dry lipid vesicles with a void-like gaseous (or air) filled core. This particular type of vesicle would have particular applicability in the paint and cosmetic industries. The two types of whiteners which presently provide the primary whitening capacity for the paint and cosmetic industries are titanium dioxide pigments (Tiθ ) and polymer particles with voids. Although Tiθ2 has a long history as a whitener, the paint and cosmetic industries have been trying to move away from this type of heavy metal whitener. Rohm & Haas developed a whitener primarily for the paint industry, sold under the trademark Rhopaquew, which is a small polymer sphere having an air space of less than 0.2 mm. This small but distinct central cavity provides optical scattering so the particle acts as a whitener. A lipid vesicle which could be dried and have a similar central cavity could provide the same whitening capacity while having the further advantages of biodegradability and cost competitiveness.
Since lipid vesicles having this type of gas-filled center cannot be made from aqueous filled vesicles, nonvolatile hydrophobic filled vesicles, or vesicles filled with highly volatile hydrophobic materials, the present invention relates to the use of moderately volatile liquids as an attempt to solve the problem. As used herein, the term "moderately volatile liquid" means and implies a liquid that is less volatile than water but more volatile than the lipids which form the bilayer structure of the vesicles. These moderately volatile liquids have a vapor pressure such that they are able to leach out of the lipid vesicles when air dried, dried under a vacuum, or lyophilized, but they do so at a slower rate than the encapsulated aqueous solution. Accordingly, substantially all of the aqueous solution encapsulated in the vesicle, as well as the aqueous solution surrounding the vesicle, evaporates before the moderately volatile liquid and the moderately volatile liquid provides structure to the vesicle as the water is removed.
Other requirements for this moderately volatile liquid included substantial immiscibility in aqueous solutions and the lipids forming the vesicles, as well as substantial unreactivity with the lipid. A class of materials which meet all these requirements are the perfluorocarbons. Perfluorocarbons are, primarily, alkanes or cycloalkanes having all of the hydrogens replaced with fluorines. Certain of these perfluorocarbons, primarily, perfluorodecalin and perfluorotripropylamine, have an additional advantage; they can function as oxygen carriers. Most perfluorocarbons have a density of about two, have a high air-and oxygen-carrying capacity, and are substantially unreactive with most materials. Encapsulation of oxygen-rich perfluorocarbons could have substantial value for use in cosmetics or in fermentation because of their high in vitro oxygenation capacity. In addition, these materials have promise for a substantial number of medical uses. For example, for these materials would be advantageous if used as an infusion after trauma, for infusion for radiotherapy, for wound perfusion, in angioplasty, or in radioimaging.
Accordingly, an object of the invention is to provide a method of encapsulating perfluorocarbons and other moderately volatile liquids.
Another object of the invention is to provide a method of forming gas-filled lipid vesicles.
A further object of the invention is to provide a whitener which could be used in a variety of industrial applications.
These and other objects and features of the invention will be apparent from the following description.
Summary of the Invention
In one aspect, the present invention features a method of making paucilamellar lipid vesicles having a moderately volatile liquid encapsulated therein as well as the vesicles themselves. In another aspect, the invention features gas-filled paucilamellar lipid vesicles. These gas-filled vesicles are made by replacing the moderately volatile liquid with a gas so as to leave a gas-filled central cavity. The gas-filled paucilamellar lipid vesicles can be used as whiteners for the paint industry, while the vesicles having the moderately volatile liquid have substantial utility as oxygen carriers.
Paucilamellar lipid vesicles having a moderately volatile liquid encapsulated therein have 2-10 lipid bilayers surrounding the large, amorphous central cavity. The first step in manufacturing these vesicles is forming a lipid phase by blending the wall-forming lipid (which provides the structure to the vesicles) and any other lipid soluble materials which are to be incorporated into the walls. One lipid soluble material which is often used is a sterol such as cholesterol which assists in the thermotropic phase transition. If any oil distinct from the moderately volatile liquid is to be encapsulated into the central cavity, it can be added at this stage or "cold loaded" later. This lipid phase is then hydrated with an excess of an aqueous phase under gentle to moderate shear to form paucilamellar lipid vesicles. If oil is added into the lipid phase, the oil fills at least part of the central core. If no oil is added, the core is filled with the aqueous hydrating solution.
The vessels can then be "cold loaded" with a moderately volatile liquid using the techniques described in United States Patent Application Serial No. 598,120. Preferably, any oil to be carried by the vesicles is loaded at this stage using the same procedure. Briefly, the formed vesicles are mixed with the moderately volatile liquid under gentle to moderate shear conditions, thereby encapsulating the moderately volatile liquid in the central cavity and driving off some (or all) of the water from the core.
Under certain circumstances, "hot loading" of the vesicles with the moderately volatile liquid is preferred. This is accomplished by dispersing or premixing the moderately volatile liquid in the lipid phase before hydration. This allows the hydration and mixing steps to be carried out simultaneously. However, using the "hot loading" technique, special care must be taken to keep the lipid phase homogeneous during hydration.
If the paucilamellar lipid vesicles having the moderately volatile liquid encapsulated therein are to be used as is, they are merely separated from the reactants. However, if gas-filled, e.g., air-filled, paucilamellar lipid vesicles are being formed, the aqueous solution and the moderately volatile liquid must be removed. This is accomplished by evaporating both liquids, e.g., by air drying, vacuum drying, or lyophilization of the vesicles. Vacuum drying is preferred. The gas-filled paucilamellar lipid vesicles may be used as a whitener because of their refractive properties.
A broad variety of wall-forming lipid materials may be used in the invention. Nonionic lipids, e.g., nonionic surfactants, are preferred. These nonionic lipids are preferably polyethylene fatty acid esters, polyethylene fatty acid ethers, diethanola ides, long chain acyl hexosa ides, long chain acyl amino acid amides, long chain amino acid amines, polyoxyethylene sorbitan esters, polyoxy glycerol mono-and diesters, glycerol mono-and distearate, glycerol mono-and dioleate, glycerol mono-and dipalmitate, and mixtures thereof. The most preferred lipids have a melting temperature of about 40°C. or greater. In addition to the nonionic lipids, certain charged lipids such as sarcosinates (sarcosinamides), betaines, and monomeric and dimeric alkyds have been found to be useful. Further, phospholipids such as phosphatidylcholine can be used.
An additional structural support material may be added to further stabilize the vesicles. This additional material is preferably a water soluble polymerizable material that provides additional structural support to the vesicles upon polymerization. Preferred water soluble polymerizable materials are gelatins, acrylates, acrylamides, alginates, carboxymethylcellulose, and similar polymers.
A moderately volatile material useful in the invention must meet the following criteria:
1. It must be less volatile than the aqueous solution in the vesicle.
2. It must be more volatile than the lipid forming the walls of the vesicle. 3. It can be evaporated or volatilized from the lipid vesicle without damaging the structural integrity of the lipid vesicle.
4. It is substantially immiscible with aqueous solutions.
5. It is substantially immiscible with the lipid forming the wall structure.
6. It is substantially unreactive with the lipid forming the wall structure.
These criteria are met by a number of materials such as certain silicones and certain mineral spirits but the perfluorocarbons are preferred. Most preferred perfluorocarbons are perfluorodecalin, perfluorohexane, perfluorooctane, and perfluorodimethylcyclohexane, perfluorotripropylamine, octafluorocyclobutane, and mixtures thereof. Most preferred perfluorocarbons are oxygen carrying molecules such as perfluorodecalin and perfluorotripropylamine.
As noted, an oil can also be incorporated into the central cavity of the vesicle. If an oil is used, it should be immiscible with the lipid forming the bilayers, immiscible with aqueous solutions, and immiscible with said moderately volatile liquid. The oil may act as a carrier for certain oil soluble materials which can be incorporated into the central cavity of the vesicle. Similarly, water soluble materials can be carried in the aqueous phase if they - li ¬
do not form crystals larger than the vesicles upon drying.
Description of the Invention
The present invention provides methods of making vesicles having gas-filled or moderately volatile liquid filled cores and the vesicles themselves. Vesicles with moderately volatile liquids can be used either on their own, e.g., as oxygen carriers, or as an intermediate in the process of manufacturing the gas-filled vesicles.
Paucilamellar lipid vesicles having aqueous or oil-filled central cavities can be manufactured using standard techniques such as those disclosed in United States Patent No. 4,911,928 or United States Patent No. 4,855,090, the disclosure of which is also incorporated herein by reference. These vesicles are then "cold loaded" with the moderately volatile liquid by mixing the preformed vesicles with the moderately volatile liquid, preferably under gentle to moderate shear conditions. A syringe technique such as is described in United States Patent Application Serial No. 598,120 is preferred. This technique provides a liquid shear which is approximately equal to a relative flow rate of about 5-50 m/s though a 1 mm radius orifice.
The perfluorocarbons are the preferred moderately volatile liquids but other materials such as certain silicone oils or volatile mineral spirits can also be used. The primary requirements are unreactivity with the lipid wall structure, immiscibility between the moderately volatile liquid and the lipid and aqueous solutions (as well as any oil to be encapsulated) and the ability to be evaporated from the vesicle without damaging the vesicle at a rate slower than the water is evaporated. Evaporation of the aqueous solutions and moderately volatile liquid can be carried out by a variety of methods. However, high heat evaporation should not be used as the lipid structure itself will be melted if too much heat is applied, thereby degrading the vesicles and defeating the purpose of the procedure. Similarly, too high a vacuum cannot be used. While lyophilization is an effective method of removing the liquids, it may be unnecessarily expensive except for large bulk production.
The following Examples will more clearly illustrate the present invention.
Example 1.
In this Example, a number of different vesicles were made using polyoxyethylene-9 glyceryl monostearate and cholesterol as the wall-forming material. First, a 3:1 ratio of polyoxyethylene-9 glyceryl monostearate and cholesterol was heated to approximately 70°C. (sufficient to obtain free flowing of the reactants) to form a lipid phase. The lipid phase was hydrated with an aqueous phase consisting of phosphate buffered saline at about 65°C. In certain of the experiments, gelatin was added as part of the aqueous phase. Hydration was accompanied by placing approximately 2 ml of the lipid in a 25 ml syringe, approximately 8 ml of the aqueous phase in a second 25 ml syringe, and connecting the two syringes via stopcock with 1 mm diameter orifice. The vesicles were made by syringing the material back and forth through the stopcock for approximately two minutes. This provides the requisite shear for vesicle formation. In fact, a method of providing "shear mixing," as the term is defined in United States Patent No. 4,911,938, would be acceptable.
Approximately 5 ml of the vesicles was blended with 1 ml of the test solution and syringed again for approximately two minutes. The test solution was water (designated "O"), perfluorooctane (a perfluorocarbon) or cyclomethicone (a silicone oil). The vesicles were then separated, observed under a light microscope to insure vesicle formation, placed on a glass slide and desiccated overnight. Table 1 lists the ingredients for each test sample.
Figure imgf000016_0001
After desiccation, a drop of oil was placed on each sample and the sample was viewed directly and under a light microscope. Sample A showed a barely noticeable haze under the microscope while samples B and C were gelatin-like. Since none of these samples included a moderately volatile oil, samples A-C provided controls for the plain water, 1% gelatin, and 1/2% gelatin aqueous phases used in forming the vesicles. However, the perfluorocarbon samples and the cyclomethicone samples all showed some level of opaqueness, indicated light refraction in the central void, of the vesicles. More particularly, sample D was intensely white and granular. Under high power microscopy, all of the opaque samples were shown to consist of packed, highly refractile granules with central voids. Upon rehydration, the granules detached as typical spherical vesicles associated with some gelatin flakes. Sample E, which was identical to sample D, except cyclomethicone replaced the perfluorooctεne, was less intensely white than sample D but still showed a white color. Similarly, sample F was intensely white (whiter than sample E) and granular. Upon rehydration, irregular shaped vesicles were apparent. Sample G was white but less intense than sample F. Sample H also showed white granules similar to those of samples E and G while sample I formed an opaque sheet of ovoid spheres. Upon rehydration, vesicles reformed in all the samples made with the moderately volatile liquids.
This Example indicates that there clearly is a void formed in the moderately volatile liquid vesicles after drying. Further, it indicates that a material like a perfluorocarbon is preferred to a cyclomethicone because of the greater white (or refractile) intensity.
Eyaπ-pJ-e 2.
In this Example, a similar test to that described in Example 1 was carried out except the lipid used to form the vesicle was polyoxyethylene-4 stearyl alcohol in lieu of the polyoxyethylene-9 glyceryl monostearate. The vesicles were prepared using 4 ml of the heated lipid solution and 16 ml of an aqueous solution, either with or without gelatin in the aqueous phase. Again, the lipid phase was heated to approximately 70°C, the aqueous phase was heated to approximately 65°C, and the phases were blended using the syringe method described in Example 1. After the vesicles were allowed to cool to room temperature, 5 ml of the vesicles were mixed with water, cyclomethicone (Dow Corning 344) or perfluorooctane in a 5 ml vesicle:1 ml moderately volatile liquid ratio using the previously described syringe technique.
The samples were vacuum dried and allowed to stand for two days in air to insure drying and each sample was observed by light microscopy under oil. Table 2 lists the materials used in forming the various samples.
Figure imgf000018_0001
Again, the first three samples (A-C) act as controls for the other samples. Under direct light microscope observation by placing a drop of oil over the dried vesicles, the solution was merely hazy if no moderately volatile liquid was used. Before drying, heterogenous large vesicles had been apparent. These materials did not rehydrate into vesicles.
Sample D also looked hazy under the oil but was somewhat more opaque than the control samples. Upon rehydration, vesicles reformed, showing that the bilayer structure still existed. Similar results were expected from samples F and H but no observation was made upon hydration.
Sample E, containing encapsulated perfluorooctane, showed results similar to those described in Example 1. This sample, when viewed under oil, was white and opaque, showing a network of vesicles. Upon rehydrating, detached vesicles were abundant. Similarly, sample G was also opaque but the vesicles seemed slightly distorted. Upon rehydration, the vesicles were more tightly held than those of sample E, e.g., they did not flow as much. The rehydrated vesicles for sample G appeared to be in the form of sheets of defined vesicles. Sample I gave similar results to sample G.
This Example establishes that the described procedure for vesicle manufacture having a moderately volatile liquid will form vesicles with a central void upon dehydration and that vesicles can be formed upon rehydration.
Example 3.
In this Example, the same procedures and materials were followed as in Examples 1 and 2 except the lipid used was glycerol monostearate. Similar results were obtained, with an inability to rehydrate vesicles without the moderately volatile liquid, a mild haze to a waxy-like surface observed under oil for the cyclomethicone vesicles, and opaque network of vesicles for the perfluorooctane vesicles. With 1% gelatin added, the hollowness of the perfluorooctane vesicles was clearly evident upon light observation. Again, all of the moderately volatile liquid filled vesicles were rehydratable.
Example 4.
In this Example, a different lipid, dimethydistearyl amine (Arosurf) was used as the primary lipid in vessel wall. A lipid phase of 12.21 g of dimethyldistearyl amine was blended with 2.74 g of cholesterol and heated to 100βC. About 2 ml of the heated lipid was then blended with 8 ml of an aqueous solution (either deionized water, 1% gelatin, or 1/2% gelatin) using the syringe method described in Example 1 to form vesicles. The vesicles were allowed to cool and 5 ml of the vesicles were syringe blended (using the method described in Example 1) with 1 ml of perfluorooctane. The resulting perfluorooctane containing vesicles were dried and observed under oil. All three perfluorooctane preparations showed opaque networks of particles with refractile edges. Upon rehydration, the vesicles were very adhesive and came off in sheets. Example 5 .
In this Example, a water soluble dye, crystal violet, was added to the hydrating solution in order to determine what was actually happening with the loading technique. About 4 ml of polyoxyethylene-9 glyceryl monostearate was heated to 70°C. and blended with 16 ml of a 0.5% crystal violet solution using the syringe technique described in Example 1. The vesicles were cooled to room temperature and 10 ml of the vesicles were blended, using the syringe technique described in Example 1, with 2 ml of perfluorodecalin. The resulting vesicles were dialyzed overnight in a 3500 molecular weight cut-off dialysis bag against 100 volumes of distilled water. This dialysis step was to remove any crystal violet which had not been encapsulated within the vesicles. After dialysis, the blue color of the vesicles remained, showing incorporation of the crystal violet into the aqueous solution in the vesicles. The vesicles were then dried under vacuum and appeared very granular. The vesicles were lyophilized and rehydrated and the blue color reappeared, showing that while the water from the aqueous solution had been driven out by the drying step, the dye itself was retained in the dried vesicles. Upon redialysis, only a small amount of the dye was released. This method could be used to provide dry storage of the water soluble active materials. Example 6.
This Example describes the ability of the vesicles of the invention to carry oil-soluble materials. The particular oil soluble material tested was a dye, oil red O.
First, the vesicles were made by blending 4 ml of polyoxyethylene-9 glyceryl monostearate with 16 ml of deionized water using the syringe technique of Example 1. After separation of the vesicles, and cooling to room temperature, 10 ml of the formed vesicles were blended with 2 ml of a mixture of 0.1% oil red 0 in mineral oil (Drakeol 19). The dye-containing oil and vesicles were syringed by the procedure of Example 1 for approximately two minutes, providing encapsulation of the oil. About 12 ml of the oil-filled vesicles were then blended with 2 ml of perfluorodecalin using the syringe technique of Example 1. The sample was observed under a light microscope before and after the addition of the perfluorodecalin. After observation, the vesicles were centrifuged for fifteen minutes at 3500 rpm. No separation of dye or perfluorodecalin was observed.
Light microscopy (1000 X) showed that before the addition of the perfluorodecalin, the oil substantially filled the central cavity. However, after the addition of perfluorodecalin, the central cavity showed a clear differentiation between the oil and the perfluorodecalin with a substantially flat boundary. This is probably because of the difference in surface tension between the two materials. After drying, the vesicles were in the form of granules with an oil center. These granules were then lyophilized and rehydrated into vesicles. Only a trace of free oil was released upon rehydration.
The foregoing Examples are purely illustrative and are expressly nonlimiting. Those skilled in the art will recognize other modifications and variations which may be made in the techniques described herein in order to practice the invention. Such other modifications and techniques are within the following claims.

Claims

What is claimed is:
1. A paucilamellar lipid vesicle comprising a large, amorphous central cavity surrounded by 2-10 lipid bilayers having a moderately volatile liquid encapsulated in said central cavity, said moderately volatile liquid having the following properties:
a) it is less volatile than aqueous solutions,
b) it is more volatile than the lipid and any materials forming said lipid bilayers,
c) it can be evaporated from said lipid vesicle without damaging the structural integrity of said lipid vesicle,
d) it is substantially immiscible with aqueous solutions,
e) it is substantially immiscible with the lipid forming said lipid bilayers, and
f) it is substantial unreactive with the lipid in said lipid bilayer.
2. The paucilamellar lipid vesicle of claim 1 wherein said moderately volatile liquid comprises a perfluorocarbon.
3. The paucilamellar vesicle of claim 2 wherein said perfluorocarbon is selected from the group consisting of perfluorodecalin, perfluorohexane, perfluorooctane, perfluorodimethylcyclohexane. perfluorotripropylamine, octafluorocyclobutane, and mixtures thereof.
4. The paucilamellar lipid vesicle of claim 3 wherein said perfluorocarbon comprises an oxygen carrying molecule.
5. The paucilamellar lipid vesicle of claim 1 further comprising an oil, said oil being immiscible with said lipid, immiscible with said aqueous solutions and immiscible with said moderately volatile liquid.
6. The paucilamellar lipid vesicle of claim 5 wherein said oil has oil-soluble materials carried therein.
7. The paucilamellar lipid vesicle of claim 1 wherein said lipid comprises a lipid with a melting temperature of at least about 40°C.
8. The paucilamellar lipid vesicle of claim 7 wherein said lipid comprises a nonionic lipid.
9. The paucilamellar lipid vesicle of claim 8 wherein said nonionic lipid is selected from the group consisting of polyoxyethylene fatty acid esters, polyoxyethylene fatty acid ethers, diethanolamides, long chain acyl hexosamides, long chain acyl amino acid amides, long chain amino acid amines, polyoxyethylene sorbitan esters, polyoxyethylene glyceryl mono-and diesters, glycerol mono-and distearate, glycerol mono-and dioleate, glycerol mono-and dipalmitate, and mixtures thereof.
10. The paucilamellar lipid vesicle of claim 1 wherein said lipid is selected from the group consisting of sarcosinamides, betaines, and monomeric and dimeric alkyds.
11. The paucilamellar lipid vesicle of claim 1 wherein said lipid comprises a phospholipid.
12. The paucilamellar lipid vesicle of claim 1 further comprising an aqueous soluble polymer which can polymerize to provide additional structural support to said lipid bilayers when polymerized.
13. The paucilamellar lipid vesicle of claim 12 wherein said polymer is selected from the group consisting of gelatin, acrylate, acrylamide, carboxymethylcellulose, alginate, and mixtures thereof.
14. Gas filled paucilamellar lipid vesicles comprising 2-10 lipid bilayers surrounding a large, amorphous central cavity, said central cavity being substantially filled with a gas.
15. The gas-filled paucilamellar lipid vesicle of claim 14 wherein said lipid comprises a lipid with a melting temperature of at least about 40βC.
16. The paucilamellar lipid vesicle of claim 15 wherein said lipid comprises a nonionic lipid.
17. The paucilamellar lipid vesicle of claim 16 wherein said nonionic lipid is selected from the group consisting of polyoxyethylene fatty acid esters, polyoxyethylene fatty acid ethers, diethanolamides, long chain acyl hexosamides, long chain acyl amino acid amides, long chain amino acid amines, polyoxyethylene sorbitan esters, polyoxyethylene glyceryl mono-and diesters, glycerol mono and distearate, glycerol mono-and dioleate, glycerol mono-and dipalmitate, and mixtures thereof.
18. The paucilamellar lipid vesicle of claim 15 wherein said lipid is selected from the group consisting of sarcosinamides, betaines, and mono-and dimeric alkyds.
19. The paucilamellar lipid vesicle of claim 15 wherein said lipid comprises a phospholipid.
20. The paucilamellar lipid vesicle of claim 14 further comprising an aqueous soluble polymer which can polymerize to provide additional structural support to said lipid bilayers when polymerized.
21. The paucilamellar lipid vesicle of claim 20 wherein said polymer is selected from the group consisting of gelatin, acrylate, acrylamide, carboxymethylcellulose, alginate, and mixtures thereof.
22. A method of manufacturing gas-filled paucilamellar lipid vesicles having 2-10 lipid bilayers surrounding a substantially amorphous, gas-filled central cavity comprising the steps of:
a) hydrating the lipid to be used as the primary structural wall material with an aqueous solution to form paucilamellar lipid vesicles filled with said aqueous solution in said central cavity,
b) mixing said lipid vesicles with a moderately volatile liquid that is (1) substantially immiscible with said lipid, (2) substantially immiscible with aqueous solutions, (3) less volatile than aqueous solutions, (4) more volatile than said lipid, (5) substantially unreactive with lipid, and (6) can be evaporated from said lipid without damaging the structural integrity of said paucilamellar lipid vesicles to form moderately volatile liquid filled paucilamellar lipid vesicles,
c) removing said aqueous solution and said moderately volatile material from said paucilamellar lipid vesicles without damaging the structural integrity of said paucilamellar lipid vesicles,
whereby said gas-filled paucilamellar vesicles are formed.
23. The method of claim 22 wherein said removing step comprises air drying.
24. The method of claim 22 wherein said removing step comprises vacuum drying.
25. The method of claim 22 wherein said removing step comprises lyophilizing.
26. The method of claim 22 wherein said moderately volatile liquid comprises a perfluorocarbon.
27. The paucilamellar vesicle of claim 26 wherein said perfluorocarbon is selected from the group consisting of perfluorodecalin, perfluorohexane, perfluorooctane, perfluorodimethylcyclohexane, perfluorotripropylamine, octafluorocyclobutane, and mixtures thereof.
28. The paucilamellar lipid vesicle of claim 22 wherein said lipid comprises a lipid with a melting temperature of at least about 40βC.
29. The method of claim 22 wherein said mixing step further comprises mixing oil that is immiscible with said lipid and immiscible in said moderately volatile liquid.
30. The method of claim 22 wherein said aqueous solution further comprises an aqueous soluble polymer which can polymerize to form additional structural support for said lipid bilayers when polymerized.
31. The paucilamellar lipid vesicle of claim 30 wherein said polymer is selected from the group consisting of gelatin, acrylate, acrylate, acrylamide, carboxymethylcellulose, alginate, and mixtures thereof.
32. The method of claim 22 comprising the step of dispersing said moderately volatile liquid in said lipid before hydration, thereby simultaneously carrying out said steps of hydrating said lipid and mixing said lipid vesicles with said moderately volatile liquid.
33. A whitener comprising the gas-filled vesicle of claim 14.
34. An oxygen carrier comprising the perfluorocarbon filled vesicle of claim 2.
PCT/US1992/001584 1991-03-01 1992-02-26 Gas and oxygen carrying lipid vesicles WO1992015284A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP4507835A JPH06507830A (en) 1991-03-01 1992-02-26 Lipid vesicles for gas and oxygen transport
AU15388/92A AU660970B2 (en) 1991-03-01 1992-02-26 Gas and oxygen carrying lipid vesicles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/662,850 US5219538A (en) 1987-03-13 1991-03-01 Gas and oxygen carrying lipid vesicles
US662,850 1991-03-01

Publications (1)

Publication Number Publication Date
WO1992015284A1 true WO1992015284A1 (en) 1992-09-17

Family

ID=24659489

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/001584 WO1992015284A1 (en) 1991-03-01 1992-02-26 Gas and oxygen carrying lipid vesicles

Country Status (6)

Country Link
US (1) US5219538A (en)
EP (1) EP0573592A4 (en)
JP (1) JPH06507830A (en)
AU (1) AU660970B2 (en)
CA (1) CA2106405A1 (en)
WO (1) WO1992015284A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012145A2 (en) * 1992-12-02 1994-06-09 Unilever Plc Cosmetic composition
WO1994016739A1 (en) * 1993-01-25 1994-08-04 Sonus Pharmaceuticals, Inc. Phase shift colloids as ultrasound contrast agents
US5393524A (en) * 1991-09-17 1995-02-28 Sonus Pharmaceuticals Inc. Methods for selecting and using gases as ultrasound contrast media
US5536489A (en) * 1993-06-04 1996-07-16 Molecular Biosystems, Inc. Emulsions as contrast agents and method of use
US5558094A (en) * 1991-09-17 1996-09-24 Sonus Pharmaceuticals, Inc. Methods for using persistent gases as ultrasound contrast media
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US5558854A (en) * 1991-09-17 1996-09-24 Sonus Pharmaceuticals Ultrasound contrast media comprising perfluoropentane and perfluorohexane gas
JPH09506098A (en) * 1993-11-30 1997-06-17 イマアーレクス・フアーマシユーチカル・コーポレーシヨン Gas microspheres for topical and subcutaneous application
EP0788348A1 (en) * 1994-09-16 1997-08-13 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
EP0802788A1 (en) * 1993-06-11 1997-10-29 UNGER, Evan C Novel therapeutic delivery systems
EP1015039A1 (en) * 1997-06-18 2000-07-05 Imarx Pharmaceutical Corp. Oxygen delivery agents and uses for the same
US6132699A (en) * 1996-03-05 2000-10-17 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
EP1252885A2 (en) * 1993-06-11 2002-10-30 Imarx Pharmaceutical Corp. Methods of preparing gas and gaseous precursor-filled microspheres
US6569404B1 (en) 1993-01-25 2003-05-27 Amersham Health A/S Phase shift colloids as ultrasound contrast agents
WO2003049706A2 (en) * 2001-11-09 2003-06-19 Or-Le-Or Ltd. Wrinkle cream comprising hydrophillic and hydrophobic particles
US9545457B2 (en) 1998-01-14 2017-01-17 Lantheus Medical Imaging, Inc. Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US10022460B2 (en) 2014-12-31 2018-07-17 Lantheus Medical Imaging, Inc. Lipid-encapsulated gas microsphere compositions and related methods
CN110639032A (en) * 2019-10-31 2020-01-03 南京景瑞康分子医药科技有限公司 High-frequency ultrasonic contrast agent and preparation method thereof
US10588988B2 (en) 2016-05-04 2020-03-17 Lantheus Medical Imaging, Inc. Methods and devices for preparation of ultrasound contrast agents

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5656211A (en) 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
DE4221256C2 (en) * 1992-06-26 1997-07-10 Lancaster Group Ag Galenic composition for topical use
DE4221268C2 (en) * 1992-06-26 1997-06-12 Lancaster Group Ag Use of a dermatological to support the oxygen transport in the skin
US5641509A (en) * 1992-06-26 1997-06-24 Lancaster Group Ag Preparation for topical use
US5643601A (en) * 1992-06-26 1997-07-01 Lancaster Group Ag Phospholipid-and fluorocarbon-containing cosmetic
US5736121A (en) 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
CA2252617A1 (en) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
DK1323434T3 (en) 1996-09-11 2007-11-12 Bristol Myers Squibb Medical I Method for diagnostic imaging of kidney regions using a contrast agent and a vasodilator
FR2757871B1 (en) * 1996-12-27 1999-03-26 Aerospatiale WATERPROOFING COMPOSITION COMPRISING A HYDROPHOBIC AGENT AND A SOLVENT, APPLICATION FOR THE REMOVAL OF SURFACE WATER IN PARTICULAR FROM WINDSCREENS OF VEHICLES OR AIRCRAFT
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6039960A (en) 1997-05-28 2000-03-21 E-L Management Corp. Water containing wax-based product
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
TW476788B (en) 1998-04-08 2002-02-21 Kimberly Clark Co A cleanser and the making process thereof
US6599441B1 (en) * 2000-07-18 2003-07-29 Emerald Biostructures, Inc. Crystallization solutions
US20040087564A1 (en) * 2002-10-31 2004-05-06 Wright D. Craig Delivery composition and method
AU2005248294A1 (en) 2004-04-07 2005-12-08 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
US8034796B2 (en) * 2004-04-07 2011-10-11 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
WO2006071659A1 (en) * 2004-12-29 2006-07-06 Trustees Of Boston University Delivery of h2 antagonists
DK2023896T3 (en) * 2006-05-19 2016-10-03 Viroblock Sa A composition for the inactivation of enveloped viruses
EP2200652B1 (en) 2007-09-27 2018-03-21 Children's Medical Center Corporation Microbubbles and methods for oxygen delivery
US10251839B2 (en) * 2008-01-22 2019-04-09 Igi Laboratories, Inc. Lipid vesicles derived from olive oil fatty acids
WO2012065060A2 (en) * 2010-11-12 2012-05-18 Children's Medical Center Corporation Gas-filled microbubbles and systems for gas delivery
US10357450B2 (en) 2012-04-06 2019-07-23 Children's Medical Center Corporation Process for forming microbubbles with high oxygen content and uses thereof
US10577554B2 (en) 2013-03-15 2020-03-03 Children's Medical Center Corporation Gas-filled stabilized particles and methods of use
CN104353088A (en) * 2014-09-30 2015-02-18 东南大学 Preparation method of lipid bubbles
WO2016164406A1 (en) * 2015-04-06 2016-10-13 The Regents Of The University Of Colorado, A Body Corporate Intraocular oxygen delivery and absorption devices and methods
WO2018160752A1 (en) 2017-02-28 2018-09-07 Children's Medical Center Corporation Stimuli-responsive particles encapsulating a gas and methods of use
CN108888767B (en) * 2018-08-10 2021-05-25 中国科学院宁波材料技术与工程研究所 Nano composite material, preparation method and application thereof
CN116917029A (en) * 2021-03-01 2023-10-20 国立大学法人东京大学 Microparticles and microparticle dispersions

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4448765A (en) * 1978-07-03 1984-05-15 National Research Development Corporation Liposomes and their use in treating human or other mammalian patients
US4536324A (en) * 1982-07-19 1985-08-20 Lion Corporation Nonionic surfactant type vesicle dispersion
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4743449A (en) * 1983-09-12 1988-05-10 Fujisawa Pharmaceutical Co., Ltd. Drug-containing lipid vesicle preparation and method for preparing them
US4776991A (en) * 1986-08-29 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Scaled-up production of liposome-encapsulated hemoglobin
US4830857A (en) * 1984-10-24 1989-05-16 L'oreal Cosmetic and pharmaceutical compositions containing niosomes and a water-soluble polyamide, and a process for preparing these compositions
US5061484A (en) * 1988-03-11 1991-10-29 Alpha Therapeutic Corporation Perfluorochemical emulsion with stabilized vesicles
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2980941A (en) * 1958-12-08 1961-04-25 Ncr Co Cleaning sheet
CA795288A (en) * 1966-11-12 1968-09-24 Chapuis Jacques Encapsulated synthetic liquid detergent and process for preparing the same
US4212758A (en) * 1978-10-20 1980-07-15 Belkevich Petr I Cleansing agents containing oleic acid, isopropanol and ethylacetate
US4297374A (en) * 1979-10-11 1981-10-27 Wess Beatrice M Skin moisturizing and cleansing cream
US4452818A (en) * 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US4742050B1 (en) * 1982-08-17 1994-06-28 Alpha Therapeutic Corp Sensitization of hypoxic tumor cells and control of growth thereof
US4900540A (en) * 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
US4814270A (en) * 1984-09-13 1989-03-21 Becton Dickinson And Company Production of loaded vesicles
US5077036A (en) * 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
US4987154A (en) * 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US5080885A (en) * 1986-01-14 1992-01-14 Alliance Pharmaceutical Corp. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4722904A (en) * 1986-12-18 1988-02-02 Fisher Scientific Company Thermodynamically-stable aqueous perfluorocarbon microemulsion useful as blood gas control or calibrator
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4942038A (en) * 1987-03-13 1990-07-17 Micro Vesicular Systems, Inc. Encapsulated humectant
US5104736A (en) * 1988-03-03 1992-04-14 Micro-Pak, Inc. Reinforced paucilamellar lipid vesicles
US5160669A (en) * 1988-03-03 1992-11-03 Micro Vesicular Systems, Inc. Method of making oil filled paucilamellar lipid vesicles
WO1989008459A1 (en) * 1988-03-11 1989-09-21 Alpha Therapeutic Corporation Perfluorochemical emulsion with stabilized vesicles
US4993415A (en) * 1988-08-19 1991-02-19 Alliance Pharmaceutical Corp. Magnetic resonance imaging with perfluorocarbon hydrides
EP0375610A3 (en) * 1988-12-19 1992-01-02 Ciba-Geigy Ag Perfluoroalkylthioglycosides
AU5666090A (en) * 1989-05-25 1990-12-18 Technology Unlimited Incorporated Insect repellant
EP0478686B1 (en) * 1989-06-22 1993-08-11 Applications Et Transferts De Technologies Avancees Atta Fluorine and phosphorous-containing amphiphilic molecules with surfactant properties
WO1991000110A1 (en) * 1989-07-05 1991-01-10 Alliance Pharmaceutical Corp. Fluorocarbon emulsions having saturated phospholipid emulsifiers
FR2658721B1 (en) * 1990-02-23 1992-06-19 Oreal METHOD FOR MANUFACTURING A COSMETIC COMPOSITION FOR APPLICATION TO HAIR, COMPOSITION OBTAINED BY THIS PROCESS AND METHOD FOR COSMETIC TREATMENT USING THE SAME.
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4448765A (en) * 1978-07-03 1984-05-15 National Research Development Corporation Liposomes and their use in treating human or other mammalian patients
US4536324A (en) * 1982-07-19 1985-08-20 Lion Corporation Nonionic surfactant type vesicle dispersion
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4743449A (en) * 1983-09-12 1988-05-10 Fujisawa Pharmaceutical Co., Ltd. Drug-containing lipid vesicle preparation and method for preparing them
US4830857A (en) * 1984-10-24 1989-05-16 L'oreal Cosmetic and pharmaceutical compositions containing niosomes and a water-soluble polyamide, and a process for preparing these compositions
US4776991A (en) * 1986-08-29 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Scaled-up production of liposome-encapsulated hemoglobin
US5061484A (en) * 1988-03-11 1991-10-29 Alpha Therapeutic Corporation Perfluorochemical emulsion with stabilized vesicles
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0573592A4 *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558854A (en) * 1991-09-17 1996-09-24 Sonus Pharmaceuticals Ultrasound contrast media comprising perfluoropentane and perfluorohexane gas
US5393524A (en) * 1991-09-17 1995-02-28 Sonus Pharmaceuticals Inc. Methods for selecting and using gases as ultrasound contrast media
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
US5573751A (en) * 1991-09-17 1996-11-12 Sonus Pharmaceuticals, Inc. Persistent gaseous bubbles as ultrasound contrast media
US5558094A (en) * 1991-09-17 1996-09-24 Sonus Pharmaceuticals, Inc. Methods for using persistent gases as ultrasound contrast media
WO1994012145A3 (en) * 1992-12-02 1994-07-21 Unilever Plc Cosmetic composition
WO1994012145A2 (en) * 1992-12-02 1994-06-09 Unilever Plc Cosmetic composition
US5707606A (en) * 1993-01-25 1998-01-13 Sonus Pharmaceuticals, Inc. Phase shift colloids as ultrasound contrast agents
KR100332166B1 (en) * 1993-01-25 2002-11-16 아머샴 헬쓰 에이에스 Phase-modified colloidal acid solution as an ultrasonic contrast agent
US5558853A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
CN1068230C (en) * 1993-01-25 2001-07-11 索纳斯药品有限公司 Phase shift colloids as ultrasound contrast agents
EP1038535A3 (en) * 1993-01-25 2003-10-29 Amersham Health AS Use of selected perfluorocarbons for the preparation of diagnostic ultrasound contrast agents
AU680652B2 (en) * 1993-01-25 1997-08-07 Ge Healthcare As Phase shift colloids as ultrasound contrast agents
US6569404B1 (en) 1993-01-25 2003-05-27 Amersham Health A/S Phase shift colloids as ultrasound contrast agents
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
EP1038535A2 (en) * 1993-01-25 2000-09-27 Sonus Pharmaceuticals, Inc. Use of selected perfluorocarbons for the preparation of diagnostic ultrasound contrast agents
US5707607A (en) * 1993-01-25 1998-01-13 Sonus Pharmaceuticals, Inc. Phase shift colloids as ultrasound contrast agents
WO1994016739A1 (en) * 1993-01-25 1994-08-04 Sonus Pharmaceuticals, Inc. Phase shift colloids as ultrasound contrast agents
US5716597A (en) * 1993-06-04 1998-02-10 Molecular Biosystems, Inc. Emulsions as contrast agents and method of use
US5536489A (en) * 1993-06-04 1996-07-16 Molecular Biosystems, Inc. Emulsions as contrast agents and method of use
US6030603A (en) * 1993-06-04 2000-02-29 Molecular Biosystems, Inc. Emulsions as contrast agents and method of use
EP1252885A2 (en) * 1993-06-11 2002-10-30 Imarx Pharmaceutical Corp. Methods of preparing gas and gaseous precursor-filled microspheres
EP0802788A4 (en) * 1993-06-11 1998-09-09 Evan C Unger Novel therapeutic delivery systems
EP0802788A1 (en) * 1993-06-11 1997-10-29 UNGER, Evan C Novel therapeutic delivery systems
EP1252885A3 (en) * 1993-06-11 2003-04-16 Imarx Pharmaceutical Corp. Methods of preparing gas and gaseous precursor-filled microspheres
JPH09506098A (en) * 1993-11-30 1997-06-17 イマアーレクス・フアーマシユーチカル・コーポレーシヨン Gas microspheres for topical and subcutaneous application
EP0788348A4 (en) * 1994-09-16 1998-04-01 Imarx Pharmaceutical Corp Container with multi-phase composition for use in diagnostic and therapeutic applications
EP0788348A1 (en) * 1994-09-16 1997-08-13 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6132699A (en) * 1996-03-05 2000-10-17 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
EP1015039A4 (en) * 1997-06-18 2002-09-11 Imarx Pharmaceutical Corp Oxygen delivery agents and uses for the same
EP1015039A1 (en) * 1997-06-18 2000-07-05 Imarx Pharmaceutical Corp. Oxygen delivery agents and uses for the same
US9545457B2 (en) 1998-01-14 2017-01-17 Lantheus Medical Imaging, Inc. Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
WO2003049706A2 (en) * 2001-11-09 2003-06-19 Or-Le-Or Ltd. Wrinkle cream comprising hydrophillic and hydrophobic particles
US6808715B2 (en) 2001-11-09 2004-10-26 Or-Le-Or Ltd. Wrinkle cream
US7294349B2 (en) 2001-11-09 2007-11-13 Or Le Or Ltd. Wrinkle cream
WO2003049706A3 (en) * 2001-11-09 2004-03-11 Or Le Or Ltd Wrinkle cream comprising hydrophillic and hydrophobic particles
US11395856B2 (en) 2014-12-31 2022-07-26 Lantheus Medical Imaging, Inc. Lipid-encapsulated gas microsphere compositions and related methods
US10583207B2 (en) 2014-12-31 2020-03-10 Lantheus Medical Imaging, Inc. Lipid-encapsulated gas microsphere compositions and related methods
US10022460B2 (en) 2014-12-31 2018-07-17 Lantheus Medical Imaging, Inc. Lipid-encapsulated gas microsphere compositions and related methods
US10588988B2 (en) 2016-05-04 2020-03-17 Lantheus Medical Imaging, Inc. Methods and devices for preparation of ultrasound contrast agents
US12097270B2 (en) 2016-05-04 2024-09-24 Lantheus Medical Imaging, Inc. Methods and devices for preparation of ultrasound contrast agents
US11344636B2 (en) 2016-07-06 2022-05-31 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US10220104B2 (en) 2016-07-06 2019-03-05 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US9913919B2 (en) 2016-07-06 2018-03-13 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11266750B2 (en) 2016-07-06 2022-03-08 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11266749B2 (en) 2016-07-06 2022-03-08 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11529431B2 (en) 2016-07-06 2022-12-20 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11857646B2 (en) 2016-07-06 2024-01-02 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11925695B2 (en) 2016-07-06 2024-03-12 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US10583208B2 (en) 2016-07-06 2020-03-10 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
CN110639032A (en) * 2019-10-31 2020-01-03 南京景瑞康分子医药科技有限公司 High-frequency ultrasonic contrast agent and preparation method thereof
CN110639032B (en) * 2019-10-31 2022-09-30 南京景瑞康分子医药科技有限公司 High-frequency ultrasonic contrast agent and preparation method thereof

Also Published As

Publication number Publication date
EP0573592A4 (en) 1994-03-18
AU1538892A (en) 1992-10-06
AU660970B2 (en) 1995-07-13
CA2106405A1 (en) 1992-09-02
JPH06507830A (en) 1994-09-08
EP0573592A1 (en) 1993-12-15
US5219538A (en) 1993-06-15

Similar Documents

Publication Publication Date Title
AU660970B2 (en) Gas and oxygen carrying lipid vesicles
Farmer et al. [18] Liposome-encapsulated hemoglobin as an artificial oxygen-carrying system
US5089181A (en) Method of dehydrating vesicle preparations for long term storage
US5104736A (en) Reinforced paucilamellar lipid vesicles
CA2133421C (en) Process for the preparation of microcapsules or liposomes of controlled sizes
Weiner et al. Liposomes as a drug delivery system
US5874111A (en) Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
US4606940A (en) Small particle formation and encapsulation
US5985354A (en) Preparation of multiwall polymeric microcapsules from hydrophilic polymers
Rathod et al. Design and evaluation of liposomal formulation of pilocarpine nitrate
EP1660227A1 (en) Method for improving the properties of amphiphile particles
WO2002049617A2 (en) Self forming, thermodynamically stable liposomes and their applications
Kikuchi et al. A polyol dilution method for mass production of liposomes
Rao Preparation of liposomes on the industrial scale: Problems and perspectives
US5173219A (en) Uniform spherical multilamellar liposomes of defined and adjustable size distribution
Elorza et al. Comparison of particle size and encapsulation parameters of three liposomal preparations
AU612631B2 (en) Dehydrating vesicule preparations for long-term storage
Crommelin et al. Liposomes as carriers for drugs and antigens: approaches to preserve their long term stability
US6537575B1 (en) Synthetic biological membrane with self organizing properties
WO2007063156A1 (en) Liposome preparation method
US20070122469A1 (en) Method for producing a vesicle dispersion
Zheng et al. Liposome microencapsulations without using any organic solvent
US4743583A (en) Sustained release protein compositions and method for making
AU753677B2 (en) Improved method for avoiding the degradation of an active principle
Kaneko et al. Formation of homogeneous liposomes with high trapping efficiency by the surface chemical method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CS JP KR NO PL RU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2106405

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992908181

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992908181

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992908181

Country of ref document: EP